<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35587645</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1744-5078</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Ocular immunology and inflammation</Title>
          <ISOAbbreviation>Ocul Immunol Inflamm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Beneficial Effect of Upadacitinib in an Adult Patient with Juvenile Idiopathic Arthritis-associated Uveitis after Unsatisfactory Response to Tofacitinib: A Case Report.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>2</EndPage>
          <MedlinePgn>1-2</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/09273948.2022.2069128</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Several case reports have been published on the effect of janus kinase inhibitors (JAK-I) on juvenile idiopathic arthritis-associated uveitis (JIAU). Both tofacitinib and baricitinib have been described as therapeutically effective in JIAU.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We here present a case of a 24-years-old female with refractory course of JIAU receiving upadacitinib therapy.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">After failing multiple conventional and biologic disease-modifying antirheumatic drugs, the patient finally achieved clinical remission on upadacitinib monotherapy, despite a previously unsatisfactory clinical response of both arthritis and uveitis to tofacitinib monotherapy.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This case suggests that switching JAK-I might be a successful strategy in the treatment of JIAU, despite previously incomplete response to other preparations.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Baquet-Walscheid</LastName>
            <ForeName>Karoline</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-9323-6711</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, St. Franziskus Hospital, Muenster, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, University of Duisburg-Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heinz</LastName>
            <ForeName>Carsten</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-2814-4327</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, St. Franziskus Hospital, Muenster, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, University of Duisburg-Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rath</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Fachklinik Bad Bentheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scheel</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, St. Franziskus-Hospital Muenster, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heiligenhaus</LastName>
            <ForeName>Arnd</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-1726-8973</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, St. Franziskus Hospital, Muenster, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, University of Duisburg-Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Ocul Immunol Inflamm</MedlineTA>
        <NlmUniqueID>9312169</NlmUniqueID>
        <ISSNLinking>0927-3948</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Janus kinase inhibitors</Keyword>
        <Keyword MajorTopicYN="N">juvenile idiopathic arthritis</Keyword>
        <Keyword MajorTopicYN="N">therapy</Keyword>
        <Keyword MajorTopicYN="N">upadacitinib</Keyword>
        <Keyword MajorTopicYN="N">uveitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>15</Hour>
          <Minute>37</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35587645</ArticleId>
        <ArticleId IdType="doi">10.1080/09273948.2022.2069128</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
